Showing 1931-1940 of 2165 results for "".
- GenSight Biologics Announces Publication Analyzing ND4-LHON Before Lumevoq Treatment in Phase 3 Trialshttps://modernod.com/news/gensight-biologics-announces-publication-analyzing-nd4-lhon-before-lumevoq-treatment-in-phase-3-trials/2479578/GenSight Biologics announced that the Journal of Neuro-Ophthalmology has published a paper on a cross-sectional analysis of the baseline (pre-treatment) characteristics of the ND4-LHON subjects enrolled in the RESCUE and REVERSE phase 3 trials of Lumevoq. The paper,* p
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- Hillrom Launches Welch Allyn PanOptic Plus Ophthalmoscopehttps://modernod.com/news/hillrom-launches-digital-physical-assessment-innovations-to-advance-connected-care/2479106/Hillrom announced technological advances to its physical assessment tools with the launch of the new Welch Allyn PanOptic Plus Ophthalmoscope and the Welch Allyn MacroView Plus Otoscope. Examining the structure of the eyes and ears is a critical part of assessing p
- Smart Contact Lens Targets Vision Improvement for Those With Impairmentshttps://modernod.com/news/smart-contact-lens-targets-vision-improvement-for-those-with-impairments/2478766/A contact lens that operates like a smartphone in the eye was the breakout but not-yet-ready-for-prime-time health tech at Consumer Electronics Show (CES) this year, according to a Medscape report. The device wields computing and imaging p
- Dyno Therapeutics Collaborates With Novartis to Develop Improved Gene Therapies With AAV Vectors Based on AI Technologyhttps://modernod.com/news/dyno-therapeutics-collaborates-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/2477740/Dyno Therapeutics announced a collaboration with Novartis to develop improved adeno-associated virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. Financial terms of the deal were not disclosed. The partnership will allow the p
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-of-phase-3-trials-for-duravyu-in-wet-amd/2482907/EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first p
- Julia Haller, MD, Named CEO of Wills Eye Hospitalhttps://modernod.com/news/julia-haller-md-named-ceo-of-wills-eye-hospital/2482897/Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, will also become the hospital's next Chief Executive Officer. Dr. Haller assumed the expanded leadership post on July 18, succeeding longtime CEO Joseph P. Bilson, who reti